Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The immune checkpoint ICOSLG is a relapse-predicting biomarker and therapeutic target in infant t(4;11) acute lymphoblastic leukemia

15 Jun 2022

Abstract excerpt

The most frequent genetic aberration leading to infant ALL (iALL) is the chromosomal translocation t(4;11), generating the fusion oncogenes KMT2A : AFF1 and AFF1 : KMT2A , respectively. KMT2A -r iALL displays a dismal prognosis through high relapse rates and relapse-associated mortality. Relapse occurs frequently despite ongoing chemotherapy and without the accumulation of secondary mutations. A rational...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Immune Cell Function and Interaction
Share to Lung Cancer Research Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35800767
DOI: 10.1016/j.isci.2022.104613

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The immune checkpoint ICOSLG is a relapse-predicting biomarker and therapeutic target in infant t(4;11) acute lymphoblastic leukemiaPMID 35800767Read ↗

Updates in the biology and therapy for infant acute lymphoblastic leukemiaSemantic proximity Read ↗

Towards targeted therapy for infant acute lymphoblastic leukaemia.Semantic proximity Read ↗

Crossing Our T’s: An Unusual Presentation of Infantile T-cell LeukemiaSemantic proximity Read ↗

Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experienceSemantic proximity Read ↗

Clinicopathologic and genetic spectrum of infantile B-lymphoblastic leukemia: a multi-institutional study.Semantic proximity Read ↗

Gene expression profiling–based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infantsSemantic proximity Read ↗

Multiple Lineage Switches in KMT2A Rearranged Infant Leukemia, Responsive to Combination Therapy with CPX-351 and InotuzumabSemantic proximity Read ↗

A human fetal liver-derived infant MLL-AF4 acute lymphoblastic leukemia model reveals a distinct fetal gene expression programSemantic proximity Read ↗

Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocolSemantic proximity Read ↗

5T4 oncofetal antigen is expressed in high risk of relapse childhood pre-B acute lymphoblastic leukemia and is associated with a more invasive and chemotactic phenotype.Semantic proximity Read ↗

Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 ProtocolSemantic proximity Read ↗

Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.